Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
© 2026 Copyright Enamine
Back
Product details:
CAS
112809-51-5
Purity
95%
Letrozole is an orally active aromatase inhibitor. It is used in the treatment of hormonally-responsive breast cancer after surgery.
Properties
Name
Letrozole
Smiles
N#CC=1C=CC(=CC1)C(C=2C=CC(C#N)=CC2)N3C=NC=N3
Targets
Please log in to see this information
SDS
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole | 4,4’-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile | 4-[(4-cyanophenyl)(1,2,4-triazol-1-yl)methyl]benzonitrile | Femara | LTZ | Letrozole | letrazole
The compound has purity validated by NMR and/or LCMS methods.
1 mg
$19
2 mg
$19
5 mg
$19
10 mg
$19
15 mg
$19
20 mg
$19
25 mg
$19
30 mg
$19
35 mg
$19
40 mg
$19
45 mg
$19
50 mg
$19
75 mg
$19
100 mg
$POA
Quantity
1
Total amount
$ 19
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole | 4,4’-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile | 4-[(4-cyanophenyl)(1,2,4-triazol-1-yl)methyl]benzonitrile | Femara | LTZ | Letrozole | letrazole
The compound has purity validated by NMR and/or LCMS methods.
Target activity features
It should be emphasized that the product may be active against a larger number of targets than shown on the card. The information represented here refers to the targets with the largest value of pX or the targets with ΔpX less than 1.5 from the largest pX value.